Share this Page:
A recent phase II clinical trial has shown that combined use of a PD-1 inhibitor and a PD-L1 inhibitor proved no more beneficial than anti-PD-1 treatment alone in metastatic renal cell carcinoma (RCC) patients who had already been treated with targeted therapy.
There was no significant difference in the primary endpoint of the study, which was anti-tumour response to the treatments; 14.3% of patients treated with the PD-1 inhibitor MEDI0680 plus durvalumab (Imfinzi), a PD-L1 inhibitor, had an objective response, as compared to 19.0% for those treated with nivolumab (Opdivo) alone.
